MedTrace Logo

Pharmacogenomic Study (Adjuvant Chemotherapy)

NCT01470404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 792

Last updated 2018-01-17

No results posted yet for this study

Summary

To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.

To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.

Conditions

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • won ki kang, MD · Samsung Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-10
Primary Completion
2013-05-10
Completion
2013-07-10

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470404 on ClinicalTrials.gov